NasdaqCM - Nasdaq Real Time Price USD

Renovaro Inc. (RENB)

Compare

0.7924

-0.0416

(-4.99%)

At close: January 10 at 4:00:00 PM EST

0.7898

-0.00

(-0.33%)

After hours: January 10 at 7:41:35 PM EST

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior

GlobeNewswire 4 days ago

RENB
-4.99%
Renovaro Issues Shareholder Letter and Provides Corporate Update

Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive anal

GlobeNewswire 4 days ago

POAI

RENB
-4.99%
Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug disco

GlobeNewswire 5 days ago

RENB
-4.99%
POAI
Predictive Oncology Announces Agreement to be Acquired by Renovaro

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders’ interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has entered into a binding letter of intent with Renovaro, I

GlobeNewswire 5 days ago

POAI

RENB
-4.99%
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiary GEDi Cube BV (a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies) DBA Ren

GlobeNewswire 12 days ago

RENB
-4.99%
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary RenovaroCube (the ‘Cube’), a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Fl

GlobeNewswire 19 days ago

RENB
-4.99%
Renovaro Regains Compliance with NASDAQ Listing Requirement

LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company’s security will continue to be listed and traded on The Nasdaq

GlobeNewswire 22 days ago

RENB
-4.99%
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul (www.nebul.com) a leading AI cloud infra

GlobeNewswire 22 days ago

RENB
-4.99%
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024. This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patie

GlobeNewswire 2 months ago

RENB
-4.99%
Renovaro Announces Strategic Restructuring and Leadership Transition

Supermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member SlateRealignment of Resources to Optimize and Commercialize RenovaroCube, the Company’s Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies Newly Appointed Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and TreatmentRestructuring to Accelera

GlobeNewswire 2 months ago

RENB
-4.99%
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomesAMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to

GlobeNewswire 3 months ago

RENB
-4.99%
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) PlatformAMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai B

GlobeNewswire 3 months ago

RENB
-4.99%
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024. “Combined, the findings that will be showcased represent key steps along the developmental pathway of Cube’s “go-to-market” strategy for its open-source AI

GlobeNewswire 3 months ago

RENB
-4.99%
RenovaroCube Announces Strategic Offering of Up to 20% Ownership

AMSTERDAM, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB. Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology for multi-omics and m

GlobeNewswire 3 months ago

RENB
-4.99%
Renovaro, Inc. Announces $10 million in Equity Committed

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage. “We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from

GlobeNewswire 6 months ago

RENB
-4.99%
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independen

GlobeNewswire 7 months ago

RENB
-4.99%
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against

GlobeNewswire 8 months ago

RENB
-4.99%
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-a

GlobeNewswire 8 months ago

RENB
-4.99%
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care

LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies. Professor Kazemier is the Clinical Dir

GlobeNewswire 8 months ago

RENB
-4.99%
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers. GEDiCube’s partnership with NVIDIA’s Inception program will

GlobeNewswire 10 months ago

RENB
-4.99%

Performance Overview

Return	RENB	S&P 500
YTD	-9.02%	-1.35%
1-Year	-82.27%	+22.51%
3-Year	-87.96%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Renovaro Inc. (RENB)

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Renovaro Issues Shareholder Letter and Provides Corporate Update

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Predictive Oncology Announces Agreement to be Acquired by Renovaro

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Renovaro Regains Compliance with NASDAQ Listing Requirement

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Renovaro Announces Strategic Restructuring and Leadership Transition

PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

Renovaro, Inc. Announces $10 million in Equity Committed

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Performance Overview